Advertisement
YOU ARE HERE: LAT HomeCollectionsSupergen Inc
IN THE NEWS

Supergen Inc

FEATURED ARTICLES
BUSINESS
July 28, 1997 | Bloomberg News
SuperGen Inc. said Oracle Corp. founder and Chairman Lawrence J. Ellison completed his purchase of a $15.3-million stake in the firm, which is developing anti-cancer drugs. In April, San Ramon, Calif.-based SuperGen said it agreed to sell a 9% stake to Ellison for $15 million, or $9 a share. SuperGen also is developing drugs to treat blood disorders and diabetes. Redwood Shores, Calif.-based Oracle is the world's largest maker of database software.
ARTICLES BY DATE
BUSINESS
March 15, 2003 | From Bloomberg News
The Food and Drug Administration accused SuperGen Inc. of making misleading claims about a cancer therapy, in the agency's first news release in 17 years warning about a medicine's promotion. The news sent the Dublin, Calif., company's shares tumbling 54 cents, or 17%, to $2.55 on Nasdaq. The FDA said a Nov. 15 SuperGen release announcing FDA approval of Mitozytrex to treat stomach and pancreatic cancer exaggerated the drug's benefits and failed to explain its risks.
Advertisement
BUSINESS
March 15, 2003 | From Bloomberg News
The Food and Drug Administration accused SuperGen Inc. of making misleading claims about a cancer therapy, in the agency's first news release in 17 years warning about a medicine's promotion. The news sent the Dublin, Calif., company's shares tumbling 54 cents, or 17%, to $2.55 on Nasdaq. The FDA said a Nov. 15 SuperGen release announcing FDA approval of Mitozytrex to treat stomach and pancreatic cancer exaggerated the drug's benefits and failed to explain its risks.
BUSINESS
December 29, 1997 | Bloomberg News
SuperGen Inc. said it won approval from the Food and Drug Administration to make in the U.S. a drug for treating a rare form of leukemia. When SuperGen had bought the drug, Nipent, from Warner-Lambert Co., in September 1996, it inherited the right to sell it but needed FDA approval for its manufacture. Nipent, known chemically as pentostatin, is used to treat hairy-cell leukemia, a rare blood disease that strikes mostly men, causes severe anemia and enlarges the spleen.
BUSINESS
December 29, 1997 | Bloomberg News
SuperGen Inc. said it won approval from the Food and Drug Administration to make in the U.S. a drug for treating a rare form of leukemia. When SuperGen had bought the drug, Nipent, from Warner-Lambert Co., in September 1996, it inherited the right to sell it but needed FDA approval for its manufacture. Nipent, known chemically as pentostatin, is used to treat hairy-cell leukemia, a rare blood disease that strikes mostly men, causes severe anemia and enlarges the spleen.
BUSINESS
January 4, 2005
* Alberto-Culver Co., the world's No. 1 seller of hair products to salons, said it bought beauty products distributor CosmoProf of Chatsworth to expand into Los Angeles and Hawaii. Terms weren't disclosed. * SuperGen Inc., the Dublin, Calif.-based maker of the Nipent leukemia drug, said it withdrew a U.S. application to sell a pancreatic cancer medicine because regulators indicated that they would reject it.
BUSINESS
June 18, 1998 | Dow Jones
NeoTherapeutics Inc. said it has named four new directors, boosting the board's size to nine from five. The Irvine biotechnology company said Eric L. Nelson, a member of the company's scientific advisory board; Stephen Runnels, executive vice president of the company; and Samuel Gulko, chief financial officer of the company, were elected to two-year terms. Joseph Rubinfeld, chief executive of SuperGen Inc., was elected to a one-year term on the board.
BUSINESS
January 14, 2000 | Dow Jones
Techniclone Corp., a Tustin developer of cancer treatments, said Thursday that it has tentatively agreed to license one of its technologies to a San Ramon, Calif., company for about $8 million. The price includes an upfront payment, certain future payments and a royalty. Techniclone said in a press release that SuperGen Inc. will license its Vascular Targeting Agent technology, which is a therapeutic treatment designed specifically to destroy vascular tumors.
BUSINESS
April 9, 1997
Larry Ellison, chairman of software company Oracle Corp., on Tuesday purchased a 9% stake in drug company SuperGen Inc., which is working to develop a new generation of cancer drugs. Oracle was not immediately available to explain the $15-million purchase, but a spokesman for San Ramon-based SuperGen said: "Larry has an interest in cancer, especially prostate cancer. A lot of his close friends like Michael Milken and [Intel Chairman] Andy Grove have had bouts with it."
BUSINESS
November 30, 2000 | Times Staff and Dow Jones
NeoTherapeutics Inc., an Irvine biopharmaceutical company specializing in nerve regeneration research, said Wednesday that it has expanded its mission by forming a cancer therapy unit. The company said in a press release that it has named Dr. Luigi Lenaz, who has held executive positions at Bristol-Myers Squibb Co. for nearly 20 years, as president of the new unit, called NeoOncoRx.
BUSINESS
July 28, 1997 | Bloomberg News
SuperGen Inc. said Oracle Corp. founder and Chairman Lawrence J. Ellison completed his purchase of a $15.3-million stake in the firm, which is developing anti-cancer drugs. In April, San Ramon, Calif.-based SuperGen said it agreed to sell a 9% stake to Ellison for $15 million, or $9 a share. SuperGen also is developing drugs to treat blood disorders and diabetes. Redwood Shores, Calif.-based Oracle is the world's largest maker of database software.
BUSINESS
May 1, 1996 | From Times Staff and Wire Reports
Interneuron Pharmaceuticals Inc. shares surged Tuesday, a day after the firm won approval to sell its anti-obesity drug, Redux, which works by making people feel they have had enough to eat. Redux, which will be sold in the U.S. by American Home Products Corp., is the first obesity drug approved by the Food and Drug Administration in more than 20 years. Announced Monday, the decision follows the recommendation of an FDA advisory panel in November. Shares in Lexington, Mass.
Los Angeles Times Articles
|